Stockscreener 앱 받기
86.19
1.49%
1.139
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics (KYMR) Receives Fast Track Designation for K - GuruFocus
FDA grants fast track status to Kymera’s KT-621 for asthma By Investing.com - Investing.com South Africa
Kymera Therapeutics Advances KT-621 with FDA Fast Track Designation for Asthma and Atopic Dermatitis Trials - Quiver Quantitative
FDA Fast Track puts Kymera's once-daily oral asthma drug in focus - Stock Titan
Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma - Bitget
KYMR SEC FilingsKymera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Gilead expands Tempus AI partnership to boost oncology pipeline - MSN
Discipline and Rules-Based Execution in KYMR Response - Stock Traders Daily
Kymera Therapeutics CBO sells $500k in KYMR stock By Investing.com - Investing.com Australia
Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 8,264 Shares - MarketBeat
Noah Goodman Sells 2,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics CBO sells $500k in KYMR stock - Investing.com
Kymera Therapeutics (KYMR) CBO trades shares under Rule 10b5-1 plan - Stock Titan
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - TradingView — Track All Markets
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline - Sahm
Gilead exercises option to license Kymera’s KT-200 - BioWorld News
H.C. Wainwright reiterates Kymera Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network
Kymera Therapeutics (NASDAQ: KYMR) brokered sale notice for 11,611 shares - Stock Titan
Gilead Sciences (GILD) Secures Exclusive Rights to KT-200 from K - GuruFocus
Gilead exercises option on Kymera’s CDK2 degrader for $45M By Investing.com - Investing.com India
Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - The Manila Times
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ... - Bluefield Daily Telegraph
CEO Change: Is now the right time to enter Kymera Therapeutics IncEarnings Growth Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Aug PostEarnings: What is the earnings history of Kymera Therapeutics Inc2026 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN
SG Americas Securities LLC Grows Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish - MSN
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - AOL.com
Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,251,134.40 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares - MarketBeat
Kymera Therapeutics COO sells $1.9 million in shares By Investing.com - Investing.com Canada
Kymera Therapeutics (NASDAQ: KYMR) director sells 12,000 shares under 10b5-1 plan - Stock Titan
KYMR (NASDAQ) director/insider plans 4,600-share option exercise; prior 7,400-share 10b5-1 sale - Stock Titan
Form 144 and 10b5-1 sales reported for KYMR (NASDAQ: KYMR) - Stock Titan
Kymera's eczema drug gets fast track designation in the United States - MSN
Layoff Watch: What are Kymera Therapeutics Incs earnings expectationsBear Alert & Free Verified High Yield Trade Plans - baoquankhu1.vn
[144] Kymera Therapeutics, Inc. SEC Filing - Stock Titan
Behavioral Patterns of KYMR and Institutional Flows - Stock Traders Daily
Aug Volume: Is Kymera Therapeutics Inc forming a bullish divergence2026 Geopolitical Influence & Fast Moving Stock Watchlists - baoquankhu1.vn
Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? - Yahoo Finance
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
0.62%
자본화:
|
볼륨(24시간):